Utilization of cancer therapies to treat CRS in patients diagnosed with COVID-19 offers promise, and there is currently a Phase III study underway using ruxolitinib, a JAK1/2 inhibitor used to treat myelofibrosis. The gene discussed is JAK1; the disease is COVID-19.